Teva Pharmaceuticals Limited

Registered number: 01077587

Annual report and financial statements for the year ended 31 December 2018

SATURDAY

A8EYQ26B

A24 28/09/2019 #121

COMPANIES HOUSE

Teva Pharmaceuticals Limited

Annual report and financial statements for the year ended 31 December 2018

Contents

	Page
Directors and advisers	1
Directors' report for the year ended 31 December 2018	2
Balance sheet as at 31 December 2018	3
Notes to the financial statements	4

Teva Pharmaceuticals Limited

Directors and advisers

Directors

D Cooper
K Innes
D Vrhovec

Registered office

Ridings Point
Whistler Drive
Castleford
West Yorkshire
WF10 5HX

Registered number
01077587

Teva Pharmaceuticals Limited

Directors' report for the year ended 31 December 2018

The directors present their annual report and the financial statements of the company for the year ended 31 December 2018.

Principal Activities

The company did not trade during the year.

Results and dividends

The company's profit for the current year was £nil (2017: £nil). The directors do not recommend the payment of a dividend (2017: £nil).

Business review and future developments

Teva Pharmaceuticals Limited is dormant and has not traded during the current or prior year. The company received no income and incurred no expenditure and therefore made neither a profit nor a loss.

Directors


The directors of the company during the year and up to the date of signing the financial statements were as follows:

R Williams	(resigned 27 June 2018)
K Innes	
D Vrhovec	
D Cooper	(appointed 12 July 2018)

Directors' Indemnities

The directors and officers of the Company are covered by liability insurance arranged by the ultimate parent company Teva Pharmaceutical Industries Limited. The insurance contains qualifying third party indemnity provisions for the purposes of the Companies Act 2006 and was in place during the year and up to the date of signing the financial statements.

On behalf of the board



D Cooper
Director

25 September 2019

Teva Pharmaceuticals Limited

Balance sheet as at 31 December 2018

	Note	2018 £'000	2017 £'000
Current assets			
Debtors	4	**4,684**	4,684
Net current assets and net assets		**4,684**	4,684
Capital and reserves			
Called up share capital	5	-	-
Profit and loss account	6	**4,684**	4,684
Total equity shareholders' funds	7	**4,684**	4,684

For the year ended 31 December 2018, the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

Directors' responsibilities:

- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 of the Companies Act 2006;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
- These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

The financial statements on pages 3 to 5 were approved by the board of directors on 25 September 2019 and were signed on its behalf by:

D Cooper
Director

Registered number 01077587

Notes to the financial statements for the year ended 31 December 2018

1 Significant accounting policies

The financial statements are prepared under the historical cost convention on the going concern basis and in accordance with the Companies Act 2006 and applicable accounting standards in the United Kingdom. The principal accounting policies are set out below and have been consistently applied throughout the current and prior year.

The company has taken advantage of the transitional provisions available to dormant companies in accordance with Financial Reporting Standard 102 (FRS 102) issued by the Financial Reporting Council. The company has elected to retain its accounting policies for measurement of assets, liabilities and equity until the balances change or the company undertakes any new transactions.

The company is included by full consolidation in the consolidated financial statements of its ultimate parent company, Teva Pharmaceutical Industries Limited, a company incorporated in Israel and whose financial statements are publicly available from the address in note 9. Consequently, the company is also exempt under the terms of FRS 1, 'Cash flow statements', from publishing a cash flow statement.

2 Operating profit

The company did not trade during the financial year and consequently made neither a profit nor a loss for the year (2017: £nil).

3 Employees and directors' remuneration

The directors received no emoluments in the year in respect of their services as directors of the company (2017: £nil). The company had no other employees during the year (2017: none).

4 Debtors

	2018	2017
	£'000	£'000
Amounts owed by group undertakings	**4,684**	4,684

Amounts owed by group undertakings are unsecured, interest-free and are repayable on demand.

5 Called up share capital

	2018	2017
	£	£
Authorised		
200 (2017: 200) ordinary shares of £1 each	**200**	200
Allotted, and fully paid		
200 (2017: 200) ordinary shares of £1 each	**200**	200

Notes to the financial statements for the year ended 31 December 2018 (continued)

6 Profit and loss account

	£'000
At 1 January 2018	4,684
Profit for the financial year	-
At 31 December 2018	**4,684**

7 Reconciliation of movement in shareholders' funds

	2018	2017
	£'000	£'000
At 31 December 2018 and at 1 January 2018	**4,684**	4,684

8 Related party transactions

The company is a wholly owned subsidiary of Teva Pharmaceutical Industries Limited whose consolidated financial statements are publicly available for inspection from the address in note 9. Consequently the company has taken advantage of the exemption available under the terms of FRS 8 not to disclose related party transactions with group companies.

9 Ultimate parent undertaking and controlling party

The company's immediate parent undertaking is Teva UK Holdings Limited incorporated in England and Wales. The directors regard Teva Pharmaceutical Industries Limited, a company incorporated in Israel, as the ultimate parent company and ultimate controlling party.

Teva Pharmaceutical Industries Limited is the parent undertaking of the largest and smallest group of undertakings to consolidate these financial statements at 31 December 2018. The consolidated financial statements of Teva Pharmaceutical Industries Limited can be obtained from 5 Basel St., Petach Tikva 49131, Israel.